SKB BIO-B

Sichuan Kolumbotai Biopharmaceutical Co., Ltd. (hereinafter referred to as “Colombotai” or the “Company”) is a biomedical company focusing on R&D, manufacturing and commercialization of innovative drugs. Since its establishment in 2016, it has always been committed to solving the medical needs of China and the world at large. With integrated drug development capabilities and comprehensive management mechanisms covering all key business functions, Kolumbotai is committed to developing differentiated treatments in-house to support the improvement of existing healthcare standards. As one of the pioneers and leading developers of antibody drug conjugates (ADC), Kolumbotai has accumulated more than ten years of experience in ADC development, and is one of the first biopharmaceutical companies in China and one of the few biopharmaceutical companies in the world to establish an integrated ADC research and development platform, OptiDC.

The company uses a systematic, adaptation-oriented approach to the world's most common or difficult to treat cancers and other diseases and conditions with large numbers of patients and unmet medical needs. After many years, the company has established integrated capabilities covering all major drug development functions, including R&D, production, quality control and commercialization, and can strategically and rapidly advance 33 differentiated and clinically valuable asset pipelines, 14 of which are in the clinical stage. With the support of three independently developed technology platforms, Colombotel already has proprietary technology in ADC, macromolecules (monoclonal antibodies (monoclonal antibodies), bispecific antibodies (dual antibodies), and small molecule drugs, etc., and has been verified by many of the company's clinical-stage drug candidates. The company has built a strong pipeline that is diverse and can exert synergistic effects in terms of drug modalities, mechanisms and indication coverage.

Decades of experience, industry relationships and extensive networks of the controlling shareholder Colon Pharmaceuticals have created favorable conditions for Klen Botai to expand its commercial infrastructure and market channels. At the same time, the clinical value of Clumbotai's pipeline and drug development capabilities have also been recognized by strategic partners around the world. To date, the company has signed nine external licensing agreements, including three licensing and cooperation agreements with MerckSharp & DohmelLC (together with its affiliate, “MSD”) to develop up to nine ADC assets for cancer treatment, with upfront and milestone payments totaling US$11.8 billion. These strategic partnerships not only prove the company's R&D and business development capabilities, but are also a key driving force for continuous innovation to build global influence and long-term growth.

Looking forward to the future, Colombotai will strive to promote the commercialization of the pipeline and enhance integrated drug development capabilities, continue to lead the development and clinical activities of drug candidates, and also strive to optimize R&D platforms and develop new technologies to support the development of innovative drugs. Colon Botai will also continue to expand cGMP production and quality control facilities and enhance internal commercialization capabilities to support future pipeline assets and achieve the goal of becoming a leading global biopharmaceutical company.